Shots: The companies collaborated to assess Turning Point’s elzovantinib (TPX-0022) in combination with EQRx’s aumolertinib in patients with EGFR mutant MET-amplified advanced NSCLC Turning Point will sponsor and conduct a P-Ib/II clinical trial to evaluate the safety, tolerability and preliminary efficacy of the combination regimen and will assume all costs associated with the trial whereas […]Read More
Shots: Seres to receive $175M up front, $125M upon the US FDA’s approval of SER-109 along with ~$225M as a commercial milestone. Seres will be responsible for development & pre-commercialization costs in the US and will be entitled to 50% of the commercial profits The agreement includes co-commercialization of microbiome therapeutics in the US and […]Read More
Shots: BridgeBio to receive ~$2.45B+ including ~$100M in up front, regulatory and commercial milestones along with royalties on net sales of Infigratinib from Helsinn Group. The agreement is expected to close in Q2’21 Helsinn to co-commercialize infigratinib in oncology and other indications except for skeletal dysplasia indications in the US and will equally share profits […]Read More
Shots: Samsung Bioepis enter into a marketing collaboration with Yuhan Corporation for the domestic sale of Adalloce in Korea to treat RA, AS, and CD Additionally, Samsung Bioepis is conducting domestic sales of Etoloce (biosimilar, enbrel) and Remaloce (biosimilar, Remicade), which have been previously released, through Yuhan Corporation Based on the contract, the cooperation between […]Read More
Shots: The collaboration will merge Microsoft’s computational services, cloud and AI with UCB’s drug discovery and development capabilities The companies intend to discover and develop medicines for people living with severe diseases in immunology and neurology. The collaboration follows UCB and Microsoft’s collaboration around COVID-19 Microsoft will provide AI technology and applied scientists to work […]Read More
Shots: The Gates Foundation will provide funding support to discover and develop in vivo gene therapy for SCD. The alliance brings together Novartis drug discovery and gene therapy expertise with Gates’ funding’s The focus of the agreement to address the disparity in access to treatments and to prioritize populations and regions bearing the greatest burden […]Read More
Shots: The alliance will investigate the effectiveness of LPC-bound EPA/DHA in preventing cognitive decline linked to AD. Aker BioMarine will supply the research team with its krill-based LPC EPA/DHA product (Lysoveta) The team will evaluate the link between genetic variations in lipid metabolism & transport of EPA/DHA across the BBB using knock-in mice for human […]Read More
Shots: Ensoma to receive $100M in up front & preclinical research payment, $10M in equity investment, and is eligible to receive $1.25B as development and commercialization milestones along with royalties on sales of each product Takeda to get exclusive WW rights Ensoma’s Engenious vectors for up to five rare disease indications. Ensoma to conduct preclinical […]Read More
Shots: MTEM to receive $70M up front and is also eligible to receive ~$1.3B as development, regulatory, and sales milestone along with royalties on future sales MTEM will be responsible for research activities to discover next-generation ETBs for multiple targets, of which BMS selected the first target. BMS to get an option to obtain an […]Read More
Shots: The companies collaborated to investigate oral delivery of Sanofi’s Nanobody based medicines, which are currently available in IV & SC formulations The collaboration will advance the formulation of therapies that are traditionally limited to injections. Nanobodies are the therapeutic proteins based on camelid-derived immunoglobulin single variable domains & have potential to treat multiple diseases […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
